Novel P53 Therapies for Head and Neck Cancer

Overview

Journal World J Otorhinolaryngol Head Neck Surg

Date 2017 Dec 6

PMID 29204550

Citations 14

Authors

Mario R Castellanos

Quintin Pan

Affiliations

Soon will be listed here.

Abstract

Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human papillomavirus E6 protein. Inactivation of p53 is associated with poor clinical response and outcome; therefore, restoration of the p53 signaling cascade may be an effective approach to ablate HNSCC cells. Viral approaches to restore p53 activity in HNSCC have been well-studied and shown modest activity in clinical trials. Recent work has focused on high-throughput screens and rational designs to identify and develop small molecules to rescue p53 function. Several p53-targeting small molecules have demonstrated very promising activity in pre-clinical studies but have yet progressed to the clinical setting. Further development of p53 therapies, in particular chemical approaches, should be prioritized and evaluated in the HNSCC setting.

Citing Articles

Curcumin: A Potential Weapon in the Prevention and Treatment of Head and Neck Cancer.

Vesela K, Kejik Z, Masarik M, Babula P, Dytrych P, Martasek P ACS Pharmacol Transl Sci. 2024; 7(11):3394-3418.

PMID: 39539276 PMC: 11555516. DOI: 10.1021/acsptsci.4c00518.

Potential Alternative Therapeutic Modalities for Management Head and Neck Squamous Cell Carcinoma: A Review.

Afshari K, Sohal K Cancer Control. 2023; 30:10732748231185003.

PMID: 37328298 PMC: 10278411. DOI: 10.1177/10732748231185003.

p53 Modulates Radiosensitivity in Head and Neck Cancers-From Classic to Future Horizons.

Mirestean C, Iancu R, Iancu D Diagnostics (Basel). 2022; 12(12).

PMID: 36553058 PMC: 9777383. DOI: 10.3390/diagnostics12123052.

Immunoexpression of p53 mutant-type in Iranian patients with primary and recurrence oral squamous cell carcinoma.

Daneste H, Sadeghzadeh A, Mokhtari M, Mohammadkhani H, Lavaee F, Moayedi J Eur J Transl Myol. 2022; 33(1).

PMID: 36413207 PMC: 10141754. DOI: 10.4081/ejtm.2022.10847.

FN1 promotes prognosis and radioresistance in head and neck squamous cell carcinoma: From radioresistant HNSCC cell line to integrated bioinformatics methods.

Tang X, Tang Q, Yang X, Xiao Z, Zhu G, Yang T Front Genet. 2022; 13:1017762.

PMID: 36212151 PMC: 9533212. DOI: 10.3389/fgene.2022.1017762.

References

Sturgis E, Cinciripini P . Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer. 2007; 110(7):1429-35. DOI: 10.1002/cncr.22963. View

OMalley Jr B, Chen S, Schwartz M, Woo S . Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995; 55(5):1080-5. View

Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E . Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001; 19(2):289-98. DOI: 10.1200/JCO.2001.19.2.289. View

Pirollo K, Hao Z, Rait A, Jang Y, Fee Jr W, Ryan P . p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene. 1997; 14(14):1735-46. DOI: 10.1038/sj.onc.1201116. View

Divya C, Pillai M . Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog. 2006; 45(5):320-32. DOI: 10.1002/mc.20170. View

Shiboski C, Schmidt B, Jordan R . Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005; 103(9):1843-9. DOI: 10.1002/cncr.20998. View

Goodrum F, Ornelles D . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 1998; 72(12):9479-90. PMC: 110444. DOI: 10.1128/JVI.72.12.9479-9490.1998. View

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef L, Masucci M . Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004; 10(12):1321-8. DOI: 10.1038/nm1146. View

Liu T, El-Naggar A, McDonnell T, Steck K, Wang M, Taylor D . Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995; 55(14):3117-22. View

10.

Fakhry C, Zhang Q, Nguyen-Tan P, Rosenthal D, El-Naggar A, Garden A . Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014; 32(30):3365-73. PMC: 4195851. DOI: 10.1200/JCO.2014.55.1937. View

11.

Ganly I, Kirn D, Eckhardt G, Rodriguez G, Soutar D, Otto R . A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000; 6(3):798-806. View

12.

Caicedo-Granados E, Lin R, Fujisawa C, Yueh B, Sangwan V, Saluja A . Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncol. 2014; 50(12):1149-56. PMC: 4678773. DOI: 10.1016/j.oraloncology.2014.09.013. View

13.

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

14.

Clayman G, El-Naggar A, Lippman S, Henderson Y, Frederick M, Merritt J . Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16(6):2221-32. DOI: 10.1200/JCO.1998.16.6.2221. View

15.

Lamont J, Nemunaitis J, Kuhn J, Landers S, McCarty T . A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000; 7(8):588-92. DOI: 10.1007/BF02725338. View

16.

Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100(4):261-9. DOI: 10.1093/jnci/djn011. View

17.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

18.

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

19.

Huibregtse J, Scheffner M, Howley P . Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol. 1993; 13(8):4918-27. PMC: 360130. DOI: 10.1128/mcb.13.8.4918-4927.1993. View

20.

Patel D, Huang S, Baglia L, McCance D . The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999; 18(18):5061-72. PMC: 1171577. DOI: 10.1093/emboj/18.18.5061. View